Skip to main content
. Author manuscript; available in PMC: 2022 Oct 14.
Published in final edited form as: Clin Cancer Res. 2022 Apr 14;28(8):1549–1559. doi: 10.1158/1078-0432.CCR-21-4049

Figure 1: Consort Diagram.

Figure 1:

Enz, enzalutamide; Enz alone, Enz 160mg daily after 12-week enzalutamide monotherapy lead in; Enz+Mif, Enz 120mg and Mif 300 mg daily after 12-week Enz lead-in; LFTs, liver function tests; Mif, mifepristone.